Inactive Instrument

Highlights F-star Therapeutics, Inc.

Equities

FSTX

US30315R1077

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

F-star Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-09-28	CI
F-Star Entered into Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generationmulti-Specific Antibodies	23-07-05	CI
F-Star Announces Licence Agreement with Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody	23-03-22	CI
F-star Therapeutics Gets Acquired by invoX Pharma for $161 Million	23-03-09	MT
Sino Biopharmaceutical Completes $161 Million Acquisition of F-star Therapeutics	23-03-08	MT
InvoX Pharma Limited completed the acquisition of F-star Therapeutics, Inc.	23-03-07	CI
F-star Therapeutics Gets Final Regulatory Nod For Acquisition by Invox Pharma	23-03-07	MT
F-star Therapeutics Shares Rally After Cfius Clears Takeover	23-03-07	DJ
F-star Therapeutics Extends invoX Deal Date to Help Address CFIUS Concerns; Shares Rise	22-12-30	MT
F-star Therapeutics Says US Regulator Blocks Merger With invoX Pharma on National Security Concern; Shares Slump	22-12-29	MT
F-star Therapeutics, Inc. Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress	22-12-06	CI
F-star Therapeutics, invoX Pharma Extend Merger Completion Date	22-11-21	MT
F-star Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
F-star Therapeutics, Inc. Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research	22-11-07	CI
F-star Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Earnings Flash (FSTX) F-STAR THERAPEUTICS Posts Q2 Loss $-0.88	22-08-11	MT
F-star Therapeutics to Grant Takeda License for Immuno-oncology Bispecific Antibody	22-07-20	MT
F-star Therapeutics, Inc. Announces A License Agreement with Takeda for A Novel Next-Generation Immuno-Oncology Bispecific Antibody	22-07-20	CI
F-star Therapeutics Shares Soar on Buyout Deal	22-06-23	DJ
Sino Biopharmaceutical Unit to Buy F-star Therapeutics for $161 Million	22-06-23	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights F-star Therapeutics, Inc.

Equities

FSTX

US30315R1077

Highlights

Filters